Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
J Neurol
    September 2025
  1. ROMANO F, Rocca MA, Pagani E, Amato MP, et al
    Effects of cognitive rehabilitation and exercise on brain structure in progressive multiple sclerosis: results from the CogEx trial.
    J Neurol. 2025;272:645.
    >> Share

  2. MORENO-NAVARRO L, Mora-Diaz S, Ruiz-Escribano-Menchen L, Sempere AP, et al
    Kappa free light chain index as a diagnostic and prognostic biomarker in multiple sclerosis.
    J Neurol. 2025;272:646.
    >> Share

  3. HABEK M, Adamec I, Gabelic T, Barun B, et al
    Diagnostic performance of the 2010, 2017, and 2024 McDonald criteria: clinical implications in multiple sclerosis.
    J Neurol. 2025;272:637.
    >> Share

  4. CHEN Y, Xie L, Cui H, Zhang Y, et al
    Autoimmune encephalitis with Anti-mGluR1 antibodies: a comprehensive review.
    J Neurol. 2025;272:623.
    >> Share

  5. ALONI R, Dror C, Barazani T, Kalron A, et al
    Wartime stress and relapse risk in people with multiple sclerosis: a prospective cohort study.
    J Neurol. 2025;272:619.
    >> Share

  6. ZHU W, Chen Y, Tian C, Wang J, et al
    Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study.
    J Neurol. 2025;272:622.
    >> Share

  7. YANG J, Li H, Zhang Y, Hu S, et al
    Effects of exercise on fatigue and quality of life in multiple sclerosis: a network meta-analysis and systematic review.
    J Neurol. 2025;272:621.
    >> Share

  8. JU Y, Geng C, Guan H
    Initiation of tocilizumab within 24 hours in acute necrotizing encephalopathy is related to a good outcome: a systematic review.
    J Neurol. 2025;272:618.
    >> Share

  9. ELLENBERGER D, Frahm N, Stahmann A, Warnke C, et al
    Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis.
    J Neurol. 2025;272:609.
    >> Share

  10. ASLAN D, Bourabia S, Kowall B, Straukiene A, et al
    The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study.
    J Neurol. 2025;272:607.
    >> Share

  11. KONG L, Tan X, Wang H, Cao L, et al
    Progressive retinal and microvascular neurodegeneration in neuromyelitis optica spectrum disorders: a longitudinal SS-OCT/OCTA study.
    J Neurol. 2025;272:606.
    >> Share

    August 2025
  12. KEVER A, Kang N, Meza C, Pogacar M, et al
    Not for everyone: examining predictors of cognitive rehabilitation success in multiple sclerosis.
    J Neurol. 2025;272:593.
    >> Share

  13. MATHEY G, Epstein J, Alix T, Julien M, et al
    Cerebrospinal fluid levels of chitinase 3-like 1 and interleukin-6 can predict response to platform therapies in relapsing multiple sclerosis.
    J Neurol. 2025;272:592.
    >> Share

  14. ADAMMEK F, Gralla W, Kupjetz M, Rademacher A, et al
    Functional exercise training in persons with multiple sclerosis: a systematic review.
    J Neurol. 2025;272:590.
    >> Share

  15. REEVES JA, Tranquille A, Bartnik A, Mohebbi M, et al
    Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis.
    J Neurol. 2025;272:585.
    >> Share

  16. SCANDIFFIO J, Langer LK, Senthilnathan V, Feng G, et al
    Effects of psychological therapies in people with multiple sclerosis: a systematic review and network meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:584.
    >> Share

  17. GUERRIERI S, Gattuso I, Genchi A, Nozzolillo A, et al
    Stratify and ImmunoWELL JCV tests performances in a real-world multiple sclerosis cohort: possible clinical implications of biosimilar Natalizumab use.
    J Neurol. 2025;272:583.
    >> Share

  18. ABBADESSA G, Maida E, Bonavita S, Lavorgna L, et al
    First the B cells fall, then the T cells follow: temporal immunological shift with ocrelizumab in multiple sclerosis.
    J Neurol. 2025;272:582.
    >> Share

  19. SBAIHAT H, Roenneke K, Muller D, Ladopoulos T, et al
    MRI-based human brain atlases of R1, R2, proton density, and myelin volume fraction using synthetic quantitative imaging at 1.5 T.
    J Neurol. 2025;272:578.
    >> Share

  20. JAWORSKI M 3RD, Balconi J, Santivasci C, Youngs M, et al
    Improving conscientiousness through a smartphone app and telecoaching intervention: insights from multiple sclerosis and healthy aging samples.
    J Neurol. 2025;272:580.
    >> Share

  21. ALAM Z, Maddali A, Patel S, Weber N, et al
    Current imaging applications, radiomics, and machine learning modalities of CNS demyelinating disorders and its mimickers.
    J Neurol. 2025;272:568.
    >> Share

  22. ALFREDSSON L, Guo J, Johansson E, Olsson T, et al
    Early-life and adult body mass index in relation to MS disability progression.
    J Neurol. 2025;272:571.
    >> Share

  23. FILIPPI M, Amato MP, Centonze D, Gallo P, et al
    The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensus.
    J Neurol. 2025;272:565.
    >> Share

  24. JOHN N, Lim A, Sunthar SR, Zhang L, et al
    Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis.
    J Neurol. 2025;272:563.
    >> Share

  25. PETERSSON M, Wu J, Berggren F, Schager I, et al
    Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry.
    J Neurol. 2025;272:562.
    >> Share

  26. LEITNER U, Chew SH, Blanch J, Viswanathan M, et al
    Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2025;272:560.
    >> Share

  27. MANISCALCO GT, Sparaco M, Di Gregorio M, Cafasso G, et al
    Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study.
    J Neurol. 2025;272:559.
    >> Share

  28. KERITAM O, Ascoli O, Harsanyi A, Cetin H, et al
    Advanced multiple sclerosis: an exploratory study on a neglected patient population.
    J Neurol. 2025;272:553.
    >> Share

  29. CHEN Q, Ma Y, Li Z, Yu C, et al
    Distributions and network changes of brain activity in the acute phase of anti-NMDAR encephalitis: a MEG study.
    J Neurol. 2025;272:551.
    >> Share

  30. MENASCU S, Drori T, Kalron A
    Subcortical brain volume changes linked to concern of falling in multiple sclerosis: a structural MRI study.
    J Neurol. 2025;272:552.
    >> Share

    July 2025
  31. DE SOUZA WAGNER PH, de Paiva FA, Mello JS, Silva ALM, et al
    Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis.
    J Neurol. 2025;272:546.
    >> Share

  32. HOU Y, Zhao B, Zheng J, Dai T, et al
    Clinicopathological profiling and prognosis of idiopathic inflammatory myopathy overlapping with myasthenia gravis: a retrospective cohort study.
    J Neurol. 2025;272:542.
    >> Share

  33. DINI M, Tacchini M, Gamberini G, Boschetti A, et al
    Learning as a digital hallmark of cognition in multiple sclerosis: lessons from a digital symbol digit modalities test.
    J Neurol. 2025;272:536.
    >> Share

  34. FUNG WH, Wessels MHJ, Coerver EME, de Beukelaar J, et al
    Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS).
    J Neurol. 2025;272:530.
    >> Share

  35. PAUL F, Zappacosta S, Narduzzi S, Khellaf M, et al
    Management and burden of disease in people with myelin oligodendrocyte glycoprotein antibody-associated disease: data from an international, cross-sectional survey.
    J Neurol. 2025;272:529.
    >> Share

  36. DAI Y, Yin Q, Han B, Yuan T, et al
    MOG-IgG detection in serum and cerebrospinal fluid: diagnostic implications and clinical correlates in adult-onset Chinese MOGAD patients.
    J Neurol. 2025;272:528.
    >> Share

  37. WANG R, Wang X, Sun D, Shi Z, et al
    Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD.
    J Neurol. 2025;272:521.
    >> Share

  38. DONEDDU PE, Moretti G, Di Stefano V, Falzone Y, et al
    Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis.
    J Neurol. 2025;272:515.
    >> Share

  39. VITTURI BK, Cellerino M, Boccia D, Leray E, et al
    Environmental risk factors for multiple sclerosis: a comprehensive systematic review and meta-analysis.
    J Neurol. 2025;272:513.
    >> Share

  40. RUBIN M, Cutillo G, Viti V, Margoni M, et al
    MOGAD-related epilepsy: a systematic characterization of age-dependent clinical, fluid, imaging and neurophysiological features.
    J Neurol. 2025;272:508.
    >> Share

  41. COLEMAN A, Touze A, Farag M, Pengo M, et al
    Evaluating finger-prick blood collection for remote quantification of neurofilament light in neurological diseases.
    J Neurol. 2025;272:501.
    >> Share

  42. HELLMANN MA, Steiner I, Mermelstein M, Friedman I, et al
    Familial myasthenia gravis: characterization of an Israeli cohort and systematic review of the literature.
    J Neurol. 2025;272:498.
    >> Share

  43. NICOLELLA V, Varelli M, Fasano S, Sirica R, et al
    Clinical application of age-derived cut-offs for plasma neurofilament light chain in multiple sclerosis.
    J Neurol. 2025;272:495.
    >> Share

  44. YAGIZ OZOGUL Y, Esatoglu SN, Ozogul M, Kizilkilic O, et al
    Central nervous system involvement and mimickers in ANCA associated vasculitis.
    J Neurol. 2025;272:492.
    >> Share

  45. CAGOL A, Schaedelin S, Ocampo-Pineda M, Benkert P, et al
    Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis Cohort.
    J Neurol. 2025;272:491.
    >> Share

  46. WANG Y, Nao J, Duan Y, Li Z, et al
    Therapeutic strategies targeting complement in myasthenia gravis patients.
    J Neurol. 2025;272:489.
    >> Share

  47. VAN TILBURG SJ, Kocer S, Geissler J, van Rijs W, et al
    Genetic variation of low-to-medium-affinity Fc-gamma receptors in Guillain-Barre syndrome.
    J Neurol. 2025;272:487.
    >> Share

  48. LIMA SM, Rini N, Cali A, Brighina F, et al
    Clonidine for the management of crises in stiff-person syndrome.
    J Neurol. 2025;272:485.
    >> Share

    June 2025
  49. ZACCONE T, Moiola L, Guerrieri S, Nozzolillo A, et al
    Long-term effectiveness and safety of ocrelizumab: a single-centre real-world study.
    J Neurol. 2025;272:481.
    >> Share

  50. VERCELLINO M, Marasciulo S, Bosa C, Rolando A, et al
    Added value of spinal cord MRI in detecting active disease in non-relapsing progressive multiple sclerosis patients.
    J Neurol. 2025;272:482.
    >> Share

  51. NAUTA IM, Loughlin KNM, Gravesteijn AS, van Wegen J, et al
    A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study.
    J Neurol. 2025;272:476.
    >> Share

  52. VORASOOT N, Isitan-Alkawadri C, Pillai B, Miske R, et al
    DAGLA autoantibody experience at Mayo Clinic.
    J Neurol. 2025;272:460.
    >> Share

  53. HEWAMADDUMA C, Freimer M, Genge A, Leite MI, et al
    Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.
    J Neurol. 2025;272:457.
    >> Share

  54. BURGUET VILLENA F, Cerda-Fuertes N, Hofer L, Schadelin S, et al
    Retinal neuronal loss and progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2025;272:454.
    >> Share

  55. SAMADZADEH S, Chan F, Francis A, Sani L, et al
    The impact of autoimmune comorbidities on the onset attack recovery in adults with AQP4-NMOSD and MOGAD.
    J Neurol. 2025;272:453.
    >> Share

  56. HERAUD C, Bresch S, Bourg V, Landes-Chateau C, et al
    Monitoring anti-Rituximab antibodies in myasthenia gravis affects the time to event during Rituximab treatment.
    J Neurol. 2025;272:451.
    >> Share

  57. ZANETTA C, Gasperini C, Amato MP, Centonze D, et al
    Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective.
    J Neurol. 2025;272:446.
    >> Share

  58. CHEN H
    A disproportionality analysis of nervous system adverse events associated with disease-modifying therapies in multiple sclerosis: insights from the FDA adverse event reporting system (FAERS).
    J Neurol. 2025;272:445.
    >> Share

  59. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    Correction: In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2025;272:444.
    >> Share

  60. GERAN R, Steiner OL, Krasivskaya E, Hannemann U, et al
    Inverse relation between serum neurofilament light chain and cognitive function in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2025;272:439.
    >> Share

    May 2025
  61. MACCORA S, Vinciguerra C, Messina C, Bevilacqua L, et al
    Double seronegative myasthenia gravis and mimics: a retrospective cross-sectional study by two tertiary centers in the Southern Italy.
    J Neurol. 2025;272:433.
    >> Share

  62. NEYAL N, Krey KJ, Morrison HA, Nathoo N, et al
    From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis.
    J Neurol. 2025;272:434.
    >> Share

  63. GASPERINI C, Centonze D, Conte A, Gallo P, et al
    Personalized therapy in multiple sclerosis: an Italian Delphi consensus.
    J Neurol. 2025;272:428.
    >> Share

  64. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
    Correction: Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
    J Neurol. 2025;272:423.
    >> Share

  65. ARZALLUZ-LUQUE J, Dumez P, Picard G, Benaiteau M, et al
    Clinical course and long-term outcomes in autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy.
    J Neurol. 2025;272:421.
    >> Share

  66. GIOFRE F, Lugaresi A, Baccari F, Lui E, et al
    The topography of infratentorial lesions in depression and anxiety in multiple sclerosis.
    J Neurol. 2025;272:420.
    >> Share

  67. PIGNOLO A, Vinciguerra C, Monastero R, Rini N, et al
    Rituximab in stiff-person syndrome with glutamic acid decarboxylase 65 autoantibody: a systematic review.
    J Neurol. 2025;272:417.
    >> Share

  68. DAVIES L, Shehadeh R, Watkins WJ, Jolles S, et al
    Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis.
    J Neurol. 2025;272:415.
    >> Share

  69. CAO S, Zhou X, Du J, Zhang J, et al
    Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.
    J Neurol. 2025;272:406.
    >> Share

  70. ZHANG Y, Li G, Su H, Liang Y, et al
    Effects of exercise on balance function in people with multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.
    J Neurol. 2025;272:405.
    >> Share

  71. GERVASONI E, Torchio A, Bertoni R, Chieffo R, et al
    Beyond EDSS: multidomain impairments are detectable and associated with walking disorders in low-disabled people with multiple sclerosis.
    J Neurol. 2025;272:404.
    >> Share

  72. WANG Z, Tan H, Huang W, Fan Y, et al
    Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder.
    J Neurol. 2025;272:403.
    >> Share

  73. FREEDMAN MS, Abdelhak A, Bhutani MK, Freeman J, et al
    The role of serum neurofilament light (sNfL) as a biomarker in multiple sclerosis: insights from a systematic review.
    J Neurol. 2025;272:400.
    >> Share

  74. KIM YS, Shin IJ, Park DG, Yoon JH, et al
    Hashimoto's encephalopathy with diffuse leukoencephalopathy: serial MRI and gait analysis.
    J Neurol. 2025;272:399.
    >> Share

  75. ROSSINI E, Di Stefano V, Iorio R, Habetswallner F, et al
    Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience.
    J Neurol. 2025;272:396.
    >> Share

  76. TARANU D, Balz LT, Holbrook J, Tumani V, et al
    Cognitive impairment, mood, and fatigue in various multiple sclerosis subtypes: a one-year follow-up study.
    J Neurol. 2025;272:398.
    >> Share

  77. ROCCA MA, Ratzinger S, Preziosa P, Meani A, et al
    Clinical integration of brain and cord MRI features improves differential diagnosis of multiple sclerosis.
    J Neurol. 2025;272:388.
    >> Share

  78. HU S, Liao Z, Wang R, Zhang M, et al
    Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.
    J Neurol. 2025;272:387.
    >> Share

  79. FILIPPI M, Preziosa P, Rocca MA
    Randomized controlled trials for multiple sclerosis: integrating pathology-driven outcomes to capture therapeutic efficacy.
    J Neurol. 2025;272:385.
    >> Share

  80. ROY S, Huang Y, Hu C, Fitzgerald KC, et al
    Core diagnostic features of stiff person syndrome: insights from a case-control study.
    J Neurol. 2025;272:377.
    >> Share

  81. FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al
    Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
    J Neurol. 2025;272:375.
    >> Share

  82. KOLB H, Shachaf Y, Fainberg K, Golan M, et al
    Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label study with long-term follow-up.
    J Neurol. 2025;272:374.
    >> Share

  83. HERMAN D, Tanniou J, Leray E, Pierret C, et al
    Analyzing recurrent events in multiple sclerosis: a review of statistical models with application to the MSOAC database.
    J Neurol. 2025;272:371.
    >> Share

  84. KUUTTI K, Laakso SM, Viitala M, Atula S, et al
    Mortality and causes of death for people with multiple sclerosis: a Finnish nationwide register study.
    J Neurol. 2025;272:370.
    >> Share

    April 2025
  85. CACCIAGUERRA L, Madhavan A, Sechi E, Krecke KN, et al
    Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis.
    J Neurol. 2025;272:367.
    >> Share

  86. PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al
    Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    J Neurol. 2025;272:366.
    >> Share

  87. SEERY N, Wesselingh R, Beech P, Broadley J, et al
    Multimodal prognostication of autoimmune encephalitis: an Australian autoimmune encephalitis consortium study.
    J Neurol. 2025;272:361.
    >> Share

  88. MAHMOUDI N, Renne J, Konen FF, Jendretzky KF, et al
    Added value of optic nerve lesions for multiple sclerosis diagnostic criteria.
    J Neurol. 2025;272:358.
    >> Share

  89. CAMPETELLA L, Smolik K, Farina A, Joubert B, et al
    Neurodegeneration and the immune system: lessons from autoimmune encephalitis.
    J Neurol. 2025;272:359.
    >> Share

  90. SIRIRATNAM P, Huda S, Van der Walt A, Sanfilippo P, et al
    Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.
    J Neurol. 2025;272:339.
    >> Share

  91. LEAVITT V, Mostert J, Comtois J, Moral E, et al
    Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy.
    J Neurol. 2025;272:338.
    >> Share

  92. BALSHI A, Dempsey J, Kumbar S, Leuenberger G, et al
    Correction: Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:337.
    >> Share

  93. OJHA A, Tommasin S, Piervincenzi C, Baione V, et al
    Clinical and MRI features contributing to the clinico-radiological dissociation in a large cohort of people with multiple sclerosis.
    J Neurol. 2025;272:327.
    >> Share

  94. HONG J, Gaubert M, Lefort M, Ferre JC, et al
    Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up.
    J Neurol. 2025;272:316.
    >> Share

  95. MOIOLA L, Mandelli A, Tarkowski M, Finardi A, et al
    Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab.
    J Neurol. 2025;272:314.
    >> Share

  96. LADOPOULOS T, Abbas Z, Krieger B, Bellenberg B, et al
    Neurological disability and brain grey matter atrophy in primary progressive multiple sclerosis are determined by microstructural lesional changes, but not by lesion load.
    J Neurol. 2025;272:302.
    >> Share

    March 2025
  97. KONITSIOTI AM, Laurent S, Ellenberger D, Stahmann A, et al
    MS treatment trends before, during, and after the COVID-19 pandemic: insights from the German MS Register.
    J Neurol. 2025;272:294.
    >> Share

  98. KHERBEK H, Paramasivan NK, Dasari S, Karsten C, et al
    Exploring autoantigens in autoimmune limbic encephalitis using phage immunoprecipitation sequencing.
    J Neurol. 2025;272:292.
    >> Share

  99. RITTEL JC, Hudasch D, Doppler K, Bergh FT, et al
    Intravenous immunoglobulin as first-line acute treatment in adults with autoimmune encephalitis caused by antibodies to NMDAR, LGI1 and CASPR2.
    J Neurol. 2025;272:287.
    >> Share

  100. LADEIRA F, Nobrega C, Cerqueira J
    Evaluation of the efficacy of the SARS-CoV-2 vaccine additional and booster doses in immunocompromised patients with multiple sclerosis: the COVACiMS study.
    J Neurol. 2025;272:288.
    >> Share

  101. FUJII S, Yaguchi H, Kudo A, Eguchi K, et al
    Autoimmune cerebellar ataxia with Kelch-like protein 11 antibodies in a large cohort study.
    J Neurol. 2025;272:282.
    >> Share

  102. FARINA A, Villagran-Garcia M, Abichou-Klich A, Benaiteau M, et al
    Application of the anti-IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort.
    J Neurol. 2025;272:273.
    >> Share

  103. BRIL V, Druzdz A, Grosskreutz J, Habib AA, et al
    Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.
    J Neurol. 2025;272:275.
    >> Share

  104. DING Y, Wu D, Chu H, Tang Y, et al
    Clinical characterization of diseases associated with anti-N-methyl-D-aspartate receptor encephalitis combined with anti-myelin oligodendrocyte glycoprotein antibodies in adults.
    J Neurol. 2025;272:262.
    >> Share

  105. SORENSEN NV, Nilsson AC, Dos AH, Stenor CM, et al
    Anti-GFAP associated opsoclonus-myoclonus-ataxia syndrome in a patient with multiple autoimmune comorbidities-a case report.
    J Neurol. 2025;272:263.
    >> Share

  106. KOMATSU T, Motegi H, Mimori M, Okumura M, et al
    Predictors of achieving minimal manifestations or better status in ocular myasthenia gravis with immunotherapy.
    J Neurol. 2025;272:243.
    >> Share

  107. BOSTAN M, Li C, Cheong JW, Wong DWK, et al
    Longitudinal analysis of retinal and choriocapillaris in patients with multiple sclerosis: a 3-year study.
    J Neurol. 2025;272:237.
    >> Share

    February 2025
  108. AZZIMONTI M, Preziosa P, Pagani E, Meani A, et al
    Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.
    J Neurol. 2025;272:228.
    >> Share

  109. PARAMASIVAN NK, Sarker P, Zekeridou A, Staff NP, et al
    Upper motor neuron-predominant motor neuron disease: a novel immunotherapy-responsive association of GAD65 autoimmunity.
    J Neurol. 2025;272:230.
    >> Share

  110. BINKS SNM, Morse IM, Ashraghi M, Vincent A, et al
    Myasthenia gravis in 2025: five new things and four hopes for the future.
    J Neurol. 2025;272:226.
    >> Share

  111. SCHONHERR C, Ziegler J, Zentek T, Rashid A, et al
    Smartphone-based gait analysis in the assessment of fatigue and fatigability in people with multiple sclerosis: a supervised cohort study.
    J Neurol. 2025;272:217.
    >> Share

  112. BALSHI A, Dempsey J, Manning N, Leuenberger G, et al
    A disproportionality analysis of surgical site infections across multiple sclerosis disease modifying therapies.
    J Neurol. 2025;272:223.
    >> Share

  113. NAYAK S, Wagshul ME, Foley FW, Motl RW, et al
    Associations between connectivity in functional brain networks and gait speed in older adults with and without multiple sclerosis.
    J Neurol. 2025;272:216.
    >> Share

  114. DI SABATINO E, Ferraro D, Gaetani L, Emiliano E, et al
    CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective.
    J Neurol. 2025;272:211.
    >> Share

  115. MARASTONI D, Sicchieri M, Pizzini FB, Scartezzini A, et al
    Multiple sclerosis diagnosis and its differential diagnosis in patients presenting with type four 'mirror pattern' CSF oligoclonal bands.
    J Neurol. 2025;272:207.
    >> Share

  116. NISHIMORI Y, Tanboon J, Oyama M, Motegi H, et al
    Anti-mitochondrial M2 antibody-positive myositis may be an independent subtype of autoimmune myositis.
    J Neurol. 2025;272:206.
    >> Share

  117. CHEN X, Wang R, Li R, Hu S, et al
    A real-world study on the utility of regular rituximab treatment for neuromyelitis optica spectrum disorder.
    J Neurol. 2025;272:194.
    >> Share

  118. FILIPPI M, Amato MP, Avolio C, Gallo P, et al
    Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion.
    J Neurol. 2025;272:179.
    >> Share

  119. HANSEL M, Reichmann H, Haehner A, Schmitz-Peiffer H, et al
    Hippocampal dysfunction after autoimmune encephalitis depending on the antibody type.
    J Neurol. 2025;272:175.
    >> Share

    January 2025
  120. GIANNOPAPAS V, Smyrni V, Kitsos DK, Stefanou MI, et al
    Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis.
    J Neurol. 2025;272:162.
    >> Share

  121. DE ARMAS FERNANDEZ JR, Garcia CEP, Herrera BA, Garcia FD, et al
    Incidence of Guillain-Barre syndrome in Cuba before and during the Oropouche virus emergency, 2018-2024.
    J Neurol. 2025;272:164.
    >> Share

  122. BOAVENTURA M, Fragoso DC, Avolio I, Pereira SA, et al
    Brain tissue integrity in neuromyelitis optica spectrum disorder through T1-w/T2-w ratio, MTR and DTI.
    J Neurol. 2025;272:157.
    >> Share

  123. INOJOSA H, Schriefer D, Ness NH, Dillenseger A, et al
    Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
    J Neurol. 2025;272:153.
    >> Share

  124. PIHL-JENSEN G, Frederiksen JL
    The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with optic neuritis.
    J Neurol. 2025;272:131.
    >> Share

  125. LAGEMAN SB, Jolly A, Sahi N, Prados F, et al
    Explaining cognitive function in multiple sclerosis through networks of grey and white matter features: a joint independent component analysis.
    J Neurol. 2025;272:142.
    >> Share

  126. MIRMOSAYYEB O, Weinstock-Guttman B, Zivadinov R, Jakimovski D, et al
    Anatomy-driven segmentation of parafoveal optical coherence tomography (OCT) measures may improve associations with clinical outcomes in multiple sclerosis.
    J Neurol. 2025;272:141.
    >> Share

  127. BALSHI A, Dempsey J, Kumbar S, Leunberger G, et al
    Marriage is associated with decreased lesion volumes and less brain atrophy in people with multiple sclerosis.
    J Neurol. 2025;272:151.
    >> Share

  128. MAR S, Valeriani M, Steinborn B, Schreiner T, et al
    Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study.
    J Neurol. 2025;272:137.
    >> Share

  129. MAIWORM M, Koerbel K, Anschutz V, Jakob J, et al
    BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients.
    J Neurol. 2025;272:147.
    >> Share

  130. PREZIOSA P, Pagani E, Meani A, Margoni M, et al
    Soma and neurite density abnormalities of paramagnetic rim lesions and core-sign lesions in multiple sclerosis.
    J Neurol. 2025;272:145.
    >> Share

  131. PLESS S, Woelfle T, Lorscheider J, Wiencierz A, et al
    CoGames: Development of an adaptive smartphone-based and gamified monitoring tool for cognitive function in Multiple Sclerosis.
    J Neurol. 2025;272:119.
    >> Share

  132. ZANGHI A, Greco A, Giancipoli E, Tumani H, et al
    Unraveling the inflammation-degeneration tangle in early MS: preliminary insights from ferritin, neurogranin, TREM2, and retinal ganglion cell layer.
    J Neurol. 2025;272:109.
    >> Share

  133. FOCKE JK, Brokbals M, Becker J, Veltkamp R, et al
    Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review.
    J Neurol. 2025;272:135.
    >> Share

  134. LIU M, Ren H, Yao D, Yao M, et al
    Autoimmune cerebellar ataxia associated with anti-SEZ6L2 antibody: report of three cases.
    J Neurol. 2025;272:127.
    >> Share

  135. ROBERTSON NP
    Bruton's tyrosine kinase inhibitor for multiple sclerosis: new hope or false dawn.
    J Neurol. 2025;272:106.
    >> Share

  136. FAROOQI AM, Sawalha A, Omidi SJ, Dubey D, et al
    Seizures and status epilepticus in anti-NMDA receptor encephalitis.
    J Neurol. 2025;272:95.
    >> Share

  137. WALBAUM M, Madhukar A, Dobson R, Cyhlarova E, et al
    Cost effectiveness of different treatment strategies with natalizumab for pregnant women with multiple sclerosis.
    J Neurol. 2025;272:93.
    >> Share

  138. FILIPPI M, Gallo P, Gasperini C, Marfia GA, et al
    Implementing proximity care for people with multiple sclerosis in Italy: the bottom-up approach of the StayHome project.
    J Neurol. 2025;272:96.
    >> Share

  139. SCHUMACHER A, Hieke A, Spenner M, Schmitz F, et al
    Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry.
    J Neurol. 2025;272:100.
    >> Share

    December 2024
  140. NICOLESCU M, Haussler V, Paul F, Oertel FC, et al
    Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision.
    J Neurol. 2024;272:86.
    >> Share

  141. BARBA L, Gaetani L, Sperandei S, Di Sabatino E, et al
    CSF synaptic biomarkers and cognitive impairment in multiple sclerosis.
    J Neurol. 2024;272:85.
    >> Share

  142. MIRMOSAYYEB O, Yazdan Panah M, Moases Ghaffary E, Vaheb S, et al
    Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.
    J Neurol. 2024;272:77.
    >> Share

  143. INAN B, Ozturk B, Ata N, Ulgu MM, et al
    A nationwide epidemiological study of myasthenia gravis in Turkey.
    J Neurol. 2024;272:5.
    >> Share

  144. VECCHIO D, Puricelli C, Virgilio E, Passarelli F, et al
    Kappa index for multiple sclerosis diagnosis: an accurate biomarker of intrathecal synthesis.
    J Neurol. 2024;272:30.
    >> Share

  145. PONZIO M, Santoni L, Molina M, Tavazzi E, et al
    Economic burden of multiple sclerosis in an Italian cohort of patients on disease-modifying therapy: analysis of disease cost and its components.
    J Neurol. 2024;272:50.
    >> Share

  146. DE BLASIIS P, Massimiani A, Inglese C, Bianchini E, et al
    Spasticity patterns assessment and recognition for therapeutic approaches (SPARTA) in multiple sclerosis: a multicenter epidemiological study.
    J Neurol. 2024;272:34.
    >> Share

  147. KLIMAS R, Sturm D, Altenborg A, Stylianou N, et al
    Assessing axonal pathology and disease progression in chronic inflammatory demyelinating polyneuropathy using corneal confocal microscopy.
    J Neurol. 2024;272:51.
    >> Share

  148. BUGGE C, Engebretsen I, Kristiansen IS, Saether EM, et al
    Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) - a register-based study.
    J Neurol. 2024;272:15.
    >> Share

  149. FASANO C, Bettiol A, Vastola M, Lotti A, et al
    Effectiveness and safety of intravenous immunoglobulin for peripheral neuropathy in EGPA patients: a retrospective study.
    J Neurol. 2024;272:13.
    >> Share

  150. GASPERINI C, Battaglia MA, Balzani F, Chiarini E, et al
    Unveiling preferences in multiple sclerosis care: insights from an Italian discrete-choice experiment with patients and healthcare professionals.
    J Neurol. 2024;272:27.
    >> Share

  151. COMABELLA M, Hegen H, Villar LM, Rejdak K, et al
    Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis.
    J Neurol. 2024;272:26.
    >> Share

  152. MARLET IR, Andersen RK, Axelsen KH, Andersen LK, et al
    Factors affecting the diagnostic delay of myasthenia gravis.
    J Neurol. 2024;272:29.
    >> Share

  153. FILIPPI M, Margoni M, Zaccone T, Guerrieri S, et al
    Disability worsening outcome in multiple sclerosis based on EDSS: does half a point matter?
    J Neurol. 2024;272:9.
    >> Share

    November 2024
  154. PAKEERATHAN T, Havla J, Schwake C, Salmen A, et al
    Rapid differentiation of MOGAD and MS after a single optic neuritis.
    J Neurol. 2024;271:7222-7231.
    >> Share

    October 2024
  155. FACCIORUSSO S, Malfitano C, Giordano M, Del Furia MJ, et al
    Effectiveness of robotic rehabilitation for gait and balance in people with multiple sclerosis: a systematic review.
    J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12715.
    >> Share

  156. TARD C, Laforet P, de Pouvourville G, Crochard A, et al
    Treatment of myasthenia gravis in france: A retrospective claims database study (STAMINA).
    J Neurol. 2024 Oct 10. doi: 10.1007/s00415-024-12714.
    >> Share

  157. MOSER T, Gruber J, Mylonaki E, Bohm V, et al
    Autoimmune and infectious encephalitis: development of a discriminative tool for early diagnosis and initiation of therapy.
    J Neurol. 2024 Oct 5. doi: 10.1007/s00415-024-12712.
    >> Share

  158. BALCK A, Lange LM, Neumann A, Royl G, et al
    Highly beneficial outcome in severe acute necrotizing encephalopathy with tocilizumab treatment.
    J Neurol. 2024;271:7042-7045.
    >> Share

  159. SELMAJ K, Hartung HP, Mycko MP, Selmaj I, et al
    MS treatment de-escalation: review and commentary.
    J Neurol. 2024;271:6426-6438.
    >> Share

    September 2024
  160. MALUCCHI S, Bava CI, Valentino P, Martire S, et al
    In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting.
    J Neurol. 2024 Sep 23. doi: 10.1007/s00415-024-12701.
    >> Share

  161. PEKMEZOVIC T, Jovicevic V, Andabaka M, Momcilovic N, et al
    Aquaporin4-IgG seropositivity significantly increases the risk of comorbid autoimmune diseases in NMOSD patients: population-based registry data.
    J Neurol. 2024 Sep 22. doi: 10.1007/s00415-024-12698.
    >> Share

  162. MARGONI M, Valsasina P, Moiola L, Mistri D, et al
    Monoaminergic network abnormalities are associated with fatigue in pediatric multiple sclerosis.
    J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12689.
    >> Share

  163. MENG H, He L, Chunyu H, Zhou Q, et al
    (18)F-DPA714 PET/MRI as a potential imaging tool for detecting possible antibody-negative autoimmune encephalitis: a prospective study.
    J Neurol. 2024 Sep 19. doi: 10.1007/s00415-024-12690.
    >> Share

  164. MANGIORIS G, Orozco E, Dubey D, Flanagan EP, et al
    Long-term outcomes in antibody-negative autoimmune encephalitis: a retrospective study.
    J Neurol. 2024 Sep 15. doi: 10.1007/s00415-024-12680.
    >> Share

  165. KONITSIOTI AM, Pruss H, Laurent S, Fink GR, et al
    Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.
    J Neurol. 2024 Sep 14. doi: 10.1007/s00415-024-12642.
    >> Share

  166. YOUSEF H, Malagurski Tortei B, Castiglione F
    Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.
    J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12651.
    >> Share

  167. CLARELLI F, Corona A, Paakkonen K, Sorosina M, et al
    Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study.
    J Neurol. 2024 Sep 12. doi: 10.1007/s00415-024-12608.
    >> Share

  168. HAFSTEINSDOTTIR B, Farman H, Lagerstrom N, Zetterberg H, et al
    Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barre syndrome.
    J Neurol. 2024 Sep 9. doi: 10.1007/s00415-024-12679.
    >> Share

  169. CALLEN AM, Zurawski J, Chu R, Tie Y, et al
    The role of 7 T MRI to assess atrophy of the subcortical deep gray matter in relapsing-remitting multiple sclerosis.
    J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12656.
    >> Share

  170. DELUCA J
    Correction to: Fatigue in multiple sclerosis: can we measure it and can we treat it?
    J Neurol. 2024 Sep 6. doi: 10.1007/s00415-024-12630.
    >> Share

  171. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
    Correction to: Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    J Neurol. 2024 Sep 4. doi: 10.1007/s00415-024-12627.
    >> Share

  172. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
    Correction to: Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
    J Neurol. 2024 Sep 3. doi: 10.1007/s00415-024-12560.
    >> Share

  173. SHI Z, Kong L, Wang R, Wang X, et al
    Cytomegalovirus and Epstein-Barr virus infections in patients with neuromyelitis optica spectrum disorder.
    J Neurol. 2024;271:6089-6095.
    >> Share

  174. QUINT P, Schroeter CB, Kohle F, Ozturk M, et al
    Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort.
    J Neurol. 2024;271:5930-5943.
    >> Share

  175. HECHLER A, Kuchling J, Muller-Jensen L, Klag J, et al
    Hippocampal hub failure is linked to long-term memory impairment in anti-NMDA-receptor encephalitis: insights from structural connectome graph theoretical network analysis.
    J Neurol. 2024;271:5886-5898.
    >> Share

  176. ABBOUD H, Sun R, Modak N, Elkasaby M, et al
    Spinal movement disorders in NMOSD, MOGAD, and idiopathic transverse myelitis: a prospective observational study.
    J Neurol. 2024;271:5875-5885.
    >> Share

    August 2024
  177. WURDACK K, Pruss H, Finke C
    Evolution from viral encephalitis to autoimmune encephalitis to multiple sclerosis: a case report.
    J Neurol. 2024 Aug 31. doi: 10.1007/s00415-024-12659.
    >> Share

  178. CHISARI CG, Amato MP, Di Sapio A, Foschi M, et al
    Active and non-active secondary progressive multiple sclerosis patients exhibit similar disability progression: results of an Italian MS registry study (ASPERA).
    J Neurol. 2024 Aug 27. doi: 10.1007/s00415-024-12621.
    >> Share

  179. BAYAT M, Harbo T, Anzabi M, Bayat A, et al
    POLG-related mitochondrial disease mimicking autoimmune encephalitis.
    J Neurol. 2024 Aug 24. doi: 10.1007/s00415-024-12641.
    >> Share

  180. CAROTENUTO A, Di Monaco C, Papetti L, Borriello G, et al
    Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod.
    J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12610.
    >> Share

  181. SIMONE M, Lucisano G, Guerra T, Paolicelli D, et al
    Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
    J Neurol. 2024 Aug 23. doi: 10.1007/s00415-024-12638.
    >> Share

  182. MISCIOSCIA A, Mainero C, Treaba CA, Silvestri E, et al
    The contribution of paramagnetic rim and cortical lesions to physical and cognitive disability at multiple sclerosis clinical onset: evaluating the power of MRI and OCT biomarkers.
    J Neurol. 2024 Aug 19. doi: 10.1007/s00415-024-12622.
    >> Share

  183. DUMEZ P, Villagran-Garcia M, Bani-Sadr A, Benaiteau M, et al
    Specific clinical and radiological characteristics of anti-NMDA receptor autoimmune encephalitis following herpes encephalitis.
    J Neurol. 2024 Aug 16. doi: 10.1007/s00415-024-12615.
    >> Share

  184. KOKUBUN N, Tsuchiya T, Hamaguchi M, Ueda Y, et al
    IgG subclass shifts occurring at acute exacerbations in autoimmune nodopathies.
    J Neurol. 2024 Aug 2. doi: 10.1007/s00415-024-12597.
    >> Share

  185. ARNETT S, Chew SH, Leitner U, Hor JY, et al
    Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis.
    J Neurol. 2024;271:4794-4812.
    >> Share

  186. ARNETT SV, Prain K, Ramanathan S, Bhuta S, et al
    Long-term outcomes of ADEM-like and tumefactive presentations of CNS demyelination: a case-comparison analysis.
    J Neurol. 2024;271:5275-5289.
    >> Share

  187. KLIMAS R, Kordes A, Huckemann S, Gasz Z, et al
    The multiple roles of nerve biopsy in the diagnosis and prognosis of suspected immune neuropathies.
    J Neurol. 2024;271:5109-5121.
    >> Share

  188. RECHTMAN A, Freidman-Korn T, Zveik O, Shweiki L, et al
    Assessing the applicability of the 2023 international MOGAD panel criteria in real-world clinical settings.
    J Neurol. 2024;271:5102-5108.
    >> Share

  189. ZHANG L, Zhang Y, Li R, Zhu J, et al
    Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy.
    J Neurol. 2024;271:4991-5002.
    >> Share

  190. COLY M, Adams D, Attarian S, Bouhour F, et al
    Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome.
    J Neurol. 2024;271:4982-4990.
    >> Share

  191. ZIVADINOV R, Jakimovski D, Burnham A, Kuhle J, et al
    Neuroimaging assessment of facility-bound severely-affected MS reveals the critical role of cortical gray matter pathology: results from the CASA-MS case-controlled study.
    J Neurol. 2024;271:4949-4962.
    >> Share

    July 2024
  192. PANE C, Di Stefano V, Cuomo N, Sarnataro A, et al
    A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients.
    J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12588.
    >> Share

  193. PAPATHANASIOU A, Tench CR, Ambrose PA, Sedehizadeh S, et al
    Pre-thymectomy disease severity predicts outcome in acetylcholine receptor antibody-positive generalised myasthenia gravis.
    J Neurol. 2024 Jul 30. doi: 10.1007/s00415-024-12592.
    >> Share

  194. FILIPPI M, Pagani E, Turrini R, Bartezaghi M, et al
    Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.
    J Neurol. 2024 Jul 29. doi: 10.1007/s00415-024-12590.
    >> Share

  195. MANZANO GS, Levy M, Salky R, Mateen FJ, et al
    Assessment of international MOGAD diagnostic criteria in patients with overlapping MOG-associated disease and multiple sclerosis phenotypes.
    J Neurol. 2024 Jul 27. doi: 10.1007/s00415-024-12585.
    >> Share

  196. MITOMA H, Manto M
    Recent advances in diagnosis of immune-mediated cerebellar ataxias: novel concepts and fundamental questions on autoimmune mechanisms.
    J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12596.
    >> Share

  197. PASSALI M, Galea I, Knudsen MH, Lau LC, et al
    Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis.
    J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12587.
    >> Share

  198. HABIB AA, Klink AJ, Muppidi S, Parthan A, et al
    United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.
    J Neurol. 2024 Jul 25. doi: 10.1007/s00415-024-12569.
    >> Share

  199. KARL AS, Klimas R, Katsimpoura M, Sgodzai M, et al
    Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study.
    J Neurol. 2024 Jul 22. doi: 10.1007/s00415-024-12581.
    >> Share

  200. MOLENAAR PCG, Noteboom S, van Nederpelt DR, Krijnen EA, et al
    Digital outcome measures are associated with brain atrophy in patients with multiple sclerosis.
    J Neurol. 2024 Jul 15. doi: 10.1007/s00415-024-12516.
    >> Share

  201. RAVANO V, Andelova M, Piredda GF, Sommer S, et al
    Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis.
    J Neurol. 2024 Jul 13. doi: 10.1007/s00415-024-12568.
    >> Share

  202. VITI V, Zanetta C, Capra R, Municchi A, et al
    Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue.
    J Neurol. 2024 Jul 11. doi: 10.1007/s00415-024-12553.
    >> Share

  203. ZHU F, Wang WF, Ma CH, Liang H, et al
    Resolution of anti-LGI1-associated autoimmune encephalitis in a patient after treatment with efgartigimod.
    J Neurol. 2024 Jul 9. doi: 10.1007/s00415-024-12556.
    >> Share

  204. DELUCA J
    Fatigue in multiple sclerosis: can we measure it and can we treat it?
    J Neurol. 2024 Jul 5. doi: 10.1007/s00415-024-12524.
    >> Share

  205. ROT U, Jerala M, Horvat Ledinek A, Brecl Jakob G, et al
    Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report.
    J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12542.
    >> Share

  206. PREZIOSA P, Amato MP, Battistini L, Capobianco M, et al
    Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
    J Neurol. 2024;271:3879-3896.
    >> Share

  207. KAPPOS L, Edan G, Freedman MS, Hartung HP, et al
    Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
    J Neurol. 2024;271:4599-4609.
    >> Share

  208. ZANGHI A, Borriello G, Bonavita S, Fantozzi R, et al
    Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
    J Neurol. 2024;271:4495-4502.
    >> Share

  209. WANG R, Sun D, Wang X, Shi Z, et al
    Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder.
    J Neurol. 2024;271:4503-4512.
    >> Share

  210. HARTUNG HP, Berger T, Bermel RA, Brochet B, et al
    ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
    J Neurol. 2024;271:4348-4360.
    >> Share

  211. PESTCHANKER C, Bertado Cortez B, Lana Peixoto MA, Gortari JI, et al
    Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings.
    J Neurol. 2024;271:4292-4299.
    >> Share

  212. MAKHANI N, Lebrun-Frenay C, Siva A, Shabanova V, et al
    The diagnostic workup of children with the radiologically isolated syndrome differs by age and by sex.
    J Neurol. 2024;271:4019-4027.
    >> Share

    June 2024
  213. LAL AP, Foong YC, Sanfilippo PG, Spelman T, et al
    A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
    J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518.
    >> Share

  214. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
    Memory function in autoimmune encephalitis: a cross-sectional prospective study utilising multiple memory paradigms.
    J Neurol. 2024 Jun 25. doi: 10.1007/s00415-024-12520.
    >> Share

  215. NOTEBOOM S, Seiler M, Chien C, Rane RP, et al
    Evaluation of machine learning-based classification of clinical impairment and prediction of clinical worsening in multiple sclerosis.
    J Neurol. 2024 Jun 23. doi: 10.1007/s00415-024-12507.
    >> Share

  216. SIMANI L, Molaeipour L, Kian S, Leavitt VM, et al
    Correlation between cognitive changes and neuroradiological changes over time in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2024 Jun 18. doi: 10.1007/s00415-024-12517.
    >> Share

  217. FUNKE M, Eveslage M, Zschuntzsch J, Hagenacker T, et al
    Fatigue and associated factors in myasthenia gravis: a nationwide registry study.
    J Neurol. 2024 Jun 13. doi: 10.1007/s00415-024-12490.
    >> Share

  218. YU H, Wang X, Pan Y, Li H, et al
    Myasthenia gravis due to anti-PD-1 treatment for an advanced colon cancer patient: a case report and literature review.
    J Neurol. 2024 Jun 12. doi: 10.1007/s00415-024-12494.
    >> Share

  219. KONG X, Guo K, Liu X, Gong X, et al
    Differentiation between viral and autoimmune limbic encephalitis: a prospective cohort study with development and validation of a diagnostic model.
    J Neurol. 2024 Jun 11. doi: 10.1007/s00415-024-12468.
    >> Share

  220. GIOSSI R, Mercenari M, Filippi M, Zanetta C, et al
    Unprescribed cannabinoids and multiple sclerosis: a multicenter, cross-sectional, epidemiological study in Lombardy, Italy.
    J Neurol. 2024 Jun 7. doi: 10.1007/s00415-024-12472.
    >> Share

  221. MUCK A, Pfeuffer S, Mir L, Genau S, et al
    Myasthenic crises are associated with negative long-term outcomes in myasthenia gravis.
    J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12478.
    >> Share

  222. HERAUD C, Bresch S, Landes-Chateau C, Bourg V, et al
    Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis.
    J Neurol. 2024 Jun 5. doi: 10.1007/s00415-024-12454.
    >> Share

  223. STARK AJ, Mobley BC, Eaton JE
    Progressive leukoencephalopathy as a manifestation of primary angiitis of the central nervous system: case report and review of the literature.
    J Neurol. 2024;271:3648-3652.
    >> Share

    May 2024
  224. PORTACCIO E, Betti M, De Meo E, Addazio I, et al
    Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression.
    J Neurol. 2024 May 28. doi: 10.1007/s00415-024-12448.
    >> Share

  225. HUANG W, Zhang H, Li X, Zhang J, et al
    Prognostic factors underlying the development of drug-resistant epilepsy in patients with autoimmune encephalitis: a retrospective cohort study.
    J Neurol. 2024 May 27. doi: 10.1007/s00415-024-12432.
    >> Share

  226. CHAE J, Nguyen TT, Oh SY
    Quantification of saccadic fatigability and diagnostic efficacy for myasthenia gravis.
    J Neurol. 2024 May 26. doi: 10.1007/s00415-024-12461.
    >> Share

  227. MONTEIRO I, Nicolella V, Fiorenza M, Novarella F, et al
    The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis.
    J Neurol. 2024 May 23. doi: 10.1007/s00415-024-12434.
    >> Share

  228. FJORDSIDE L, Nissen MS, Florescu AM, Storgaard M, et al
    Validation of a risk score to differentiate autoimmune and viral encephalitis: a Nationwide Cohort Study in Denmark.
    J Neurol. 2024 May 18. doi: 10.1007/s00415-024-12392.
    >> Share

  229. CORTESE R, Battaglini M, Stromillo ML, Luchetti L, et al
    Regional hippocampal atrophy reflects memory impairment in patients with early relapsing remitting multiple sclerosis.
    J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12290.
    >> Share

  230. WOLF E, Wicklein R, Aly L, Schmaderer C, et al
    Optical coherence tomography angiography suggests different retinal pathologies in multiple sclerosis and Sjogren's syndrome.
    J Neurol. 2024 May 14. doi: 10.1007/s00415-024-12414.
    >> Share

  231. FREEDMAN DE, Oh J, Kiss A, Puopolo J, et al
    The influence of depression and anxiety on cognition in people with multiple sclerosis: a cross-sectional analysis.
    J Neurol. 2024 May 11. doi: 10.1007/s00415-024-12409.
    >> Share

  232. BARDEL B, Creange A, Bonardet N, Bapst B, et al
    Motor function in multiple sclerosis assessed by navigated transcranial magnetic stimulation mapping.
    J Neurol. 2024 May 6. doi: 10.1007/s00415-024-12398.
    >> Share

  233. GALPERIN I, Buzaglo D, Gazit E, Shimoni N, et al
    Gait and heart rate: do they measure trait or state physical fatigue in people with multiple sclerosis?
    J Neurol. 2024 May 2. doi: 10.1007/s00415-024-12339.
    >> Share

  234. PREZIOSA P, Rocca MA, Filippi M
    Radiologically isolated syndromes: to treat or not to treat?
    J Neurol. 2024;271:2370-2378.
    >> Share

  235. LEHNERER S, Herdick M, Stegherr R, Gerischer L, et al
    Burden of disease in Lambert-Eaton myasthenic syndrome: taking the patient's perspective.
    J Neurol. 2024;271:2824-2839.
    >> Share

  236. KONEN FF, Jendretzky KF, Ratuszny D, Schuppner R, et al
    Ravulizumab in myasthenic crisis: the first case report.
    J Neurol. 2024;271:2898-2901.
    >> Share

  237. BURTON JM, Youn S, Al-Ani A, Costello F, et al
    Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
    J Neurol. 2024;271:2662-2671.
    >> Share

  238. HEIDER D, Stetefeld H, Meisel A, Bosel J, et al
    POLAR: prediction of prolonged mechanical ventilation in patients with myasthenic crisis.
    J Neurol. 2024;271:2875-2879.
    >> Share

  239. RISI M, Greco G, Masciocchi S, Rigoni E, et al
    MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment.
    J Neurol. 2024;271:2840-2843.
    >> Share

  240. DOUBROVINSKAJA S, Korporal-Kuhnke M, Jarius S, Haas J, et al
    Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
    J Neurol. 2024;271:2866-2870.
    >> Share

  241. ROCCA MA, Romano F, Tedone N, Filippi M, et al
    Advanced neuroimaging techniques to explore the effects of motor and cognitive rehabilitation in multiple sclerosis.
    J Neurol. 2024 May 1. doi: 10.1007/s00415-024-12395.
    >> Share

    April 2024
  242. DIMAURO KA, Swetlik C, Cohen JA
    Management of multiple sclerosis in older adults: review of current evidence and future perspectives.
    J Neurol. 2024 Apr 30. doi: 10.1007/s00415-024-12384.
    >> Share

  243. ROSENSTEIN I, Nordin A, Sabir H, Malmestrom C, et al
    Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2024 Apr 26. doi: 10.1007/s00415-024-12389.
    >> Share

  244. FONTE J, Stabile A, de Curtis M, Di Giacomo R, et al
    Seizures in autoimmune-associated epilepsy: a long-term video-EEG monitoring study.
    J Neurol. 2024 Apr 24. doi: 10.1007/s00415-024-12385.
    >> Share

  245. NAUTA IM, van Dam M, Bertens D, Kessels RPC, et al
    Improved quality of life and psychological symptoms following mindfulness and cognitive rehabilitation in multiple sclerosis and their mediating role for cognition: a randomized controlled trial.
    J Neurol. 2024 Apr 23. doi: 10.1007/s00415-024-12327.
    >> Share

  246. SPIEZIA AL, Scalia G, Petracca M, Caliendo D, et al
    Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    J Neurol. 2024 Apr 17. doi: 10.1007/s00415-024-12362.
    >> Share

  247. HIRT J, Dembowska K, Woelfle T, Axfors C, et al
    Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
    J Neurol. 2024 Apr 16. doi: 10.1007/s00415-024-12366.
    >> Share

  248. SINGER BA, Feng J, Chiong-Rivero H
    Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption.
    J Neurol. 2024 Apr 14. doi: 10.1007/s00415-024-12305.
    >> Share

  249. ZHANG Y, Liu D, Zhang Z, Huang X, et al
    Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
    J Neurol. 2024 Apr 11. doi: 10.1007/s00415-024-12367.
    >> Share

  250. STALTER J, Pars K, Witt K
    Accelerated long-term forgetting reveals everyday memory deficits in early-stage multiple sclerosis.
    J Neurol. 2024 Apr 8. doi: 10.1007/s00415-024-12359.
    >> Share

  251. MARTINEZ-MARTINEZ L, Lacruz AC, Querol L, Cortes-Vicente E, et al
    Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12317.
    >> Share

  252. CELIK M, Baba C, Irmak C, Ozakbas S, et al
    Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
    J Neurol. 2024 Apr 5. doi: 10.1007/s00415-024-12333.
    >> Share

  253. STEFANOU MI, Giannopapas V, Kitsos DK, Chondrogianni M, et al
    Prevalence and epidemiology of stroke in patients with multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12331.
    >> Share

  254. TERAYAMA A, Kuwahara M, Yoshikawa K, Yamagishi Y, et al
    Takotsubo cardiomyopathy in Guillain-Barre syndrome.
    J Neurol. 2024 Apr 4. doi: 10.1007/s00415-024-12295.
    >> Share

  255. MAIDA E, Moccia M, Palladino R, Borriello G, et al
    ChatGPT vs. neurologists: a cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12328.
    >> Share

  256. SIGNORIELLO E, Foschi M, Lanzillo R, Frau J, et al
    Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine.
    J Neurol. 2024 Apr 3. doi: 10.1007/s00415-024-12291.
    >> Share

  257. GUERRIERI S, Rubin M, Gattuso I, Zanetta C, et al
    Can treatment adverse events be optimized by switching between different sphingosine 1-phosphate receptor modulators in multiple sclerosis? A case series.
    J Neurol. 2024 Apr 2. doi: 10.1007/s00415-024-12342.
    >> Share

  258. MCWILLIAM O, Gramkow MH, Blaabjerg M, Clemmensen FK, et al
    Differentiating anti-IgLON5 disease and Lewy body dementia: a systematic review.
    J Neurol. 2024;271:1707-1716.
    >> Share

  259. WANG Y, Hu C, Aljarallah S, Reyes Mantilla M, et al
    Expanding clinical profiles and prognostic markers in stiff person syndrome spectrum disorders.
    J Neurol. 2024;271:1861-1872.
    >> Share

  260. TEDONE N, Vizzino C, Meani A, Gallo A, et al
    The brief repeatable battery of neuropsychological tests (BRB-N) version a: update of Italian normative data from the Italian Neuroimaging Network Initiative (INNI).
    J Neurol. 2024;271:1813-1823.
    >> Share

  261. GLASER A, Butzkueven H, van der Walt A, Gray O, et al
    Big Multiple Sclerosis Data network: an international registry research network.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12303.
    >> Share

  262. HUA T, Fan H, Duan Y, Tian D, et al
    Spinal cord and brain atrophy patterns in neuromyelitis optica spectrum disorder and multiple sclerosis.
    J Neurol. 2024 Apr 1. doi: 10.1007/s00415-024-12281.
    >> Share

    March 2024
  263. GUILLEMIN C, Vandeleene N, Charonitis M, Requier F, et al
    Brain microstructure is linked to cognitive fatigue in early multiple sclerosis.
    J Neurol. 2024 Mar 28. doi: 10.1007/s00415-024-12316.
    >> Share

  264. SCHALLER-PAULE MA, Maiworm M, Schafer JH, Friedauer L, et al
    Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    J Neurol. 2024 Mar 27. doi: 10.1007/s00415-024-12299.
    >> Share

  265. MALLUCCI G, Ferraro OE, Trojano M, Amato MP, et al
    Early prediction of unfavorable evolution after a first clinical episode suggestive of multiple sclerosis: the EUMUS score.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12304.
    >> Share

  266. ZHANG H, Ma J, Feng Y, Ma H, et al
    Efgartigimod in the treatment of Guillain-Barre syndrome.
    J Neurol. 2024 Mar 26. doi: 10.1007/s00415-024-12321.
    >> Share

  267. FUCHS L, Shelly S, Vigiser I, Kolb H, et al
    Real-World experience with efgartigimod in patients with myasthenia gravis.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12293.
    >> Share

  268. PILOTTO S, Floris M, Solla P, Pugliatti M, et al
    Determinants of self-perceived quality of life in mildly disabled multiple sclerosis patients: a cross-sectional study.
    J Neurol. 2024 Mar 25. doi: 10.1007/s00415-024-12244.
    >> Share

  269. LAUVSNES MB, Zetterberg H, Blennow K, Kvaloy JT, et al
    Correction to: Neurofilament light in plasma is a potential biomarker of central nervous system involvement in systemic lupus erythematosus.
    J Neurol. 2024 Mar 23. doi: 10.1007/s00415-024-12238.
    >> Share

  270. GOERECI Y, Ellenberger D, Rommer P, Dunkl V, et al
    Persons with multiple sclerosis older than 55 years: an analysis from the German MS registry.
    J Neurol. 2024 Mar 22. doi: 10.1007/s00415-024-12286.
    >> Share

  271. ALBERGONI M, Pagani E, Preziosa P, Meani A, et al
    Thalamic nuclei volume partially mediates the effects of aerobic capacity on fatigue in people with multiple sclerosis.
    J Neurol. 2024 Mar 20. doi: 10.1007/s00415-024-12277.
    >> Share

  272. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    Correction to: The impact of metformin use on the outcomes of relapse?remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open?label randomized controlled trial.
    J Neurol. 2024 Mar 18. doi: 10.1007/s00415-024-12249.
    >> Share

  273. VILASECA A, Farina A, Villagran-Garcia M, Pegat A, et al
    Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
    J Neurol. 2024 Mar 11. doi: 10.1007/s00415-024-12252.
    >> Share

  274. KRIJNEN EA, Broeders TAA, Noteboom S, van Dam M, et al
    The cognitive relevance of non-lesional damage to cortical networks in people with multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12240.
    >> Share

  275. HEGEN H, Berek K, Deisenhammer F, Berger T, et al
    Sex impacts treatment decisions in multiple sclerosis.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12270.
    >> Share

  276. HECHENBERGER S, Helmlinger B, Tinauer C, Jauk E, et al
    Evaluation of a self-administered iPad((R))-based processing speed assessment for people with multiple sclerosis in a clinical routine setting.
    J Neurol. 2024 Mar 5. doi: 10.1007/s00415-024-12274.
    >> Share

  277. ZID Y, Robertson NP
    Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials.
    J Neurol. 2024 Mar 4. doi: 10.1007/s00415-024-12273.
    >> Share

  278. LI J, Wu X, Chu T, Tan X, et al
    The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2024 Mar 3. doi: 10.1007/s00415-024-12247.
    >> Share

  279. GUGER M, Enzinger C, Leutmezer F, Di Pauli F, et al
    Early intensive versus escalation treatment in patients with relapsing-remitting multiple sclerosis in Austria.
    J Neurol. 2024 Mar 2. doi: 10.1007/s00415-024-12256.
    >> Share

    February 2024
  280. SCHERER L, Soudant M, Pittion-Vouyovitch S, Debouverie M, et al
    Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study.
    J Neurol. 2024 Feb 29. doi: 10.1007/s00415-024-12266.
    >> Share

  281. TOLJAN K, Briggs FBS
    Male sexual and reproductive health in multiple sclerosis: a scoping review.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-024-12250.
    >> Share

  282. LEAVITT VM, Tozlu C, Nelson KE, Boehme AK, et al
    A randomized controlled trial of oral antipyretic treatment to reduce overheating during exercise in adults with multiple sclerosis.
    J Neurol. 2024 Feb 28. doi: 10.1007/s00415-023-12147.
    >> Share

  283. VAN DAM M, Krijnen EA, Nauta IM, Fuchs TA, et al
    Identifying and understanding cognitive profiles in multiple sclerosis: a role for visuospatial memory functioning.
    J Neurol. 2024 Feb 26. doi: 10.1007/s00415-024-12227.
    >> Share

  284. NGUYEN TT, Chae J, Kang JJ, Oh SY, et al
    Saccadic fatigue as an early indicator for diagnosing myasthenia gravis.
    J Neurol. 2024 Feb 25. doi: 10.1007/s00415-024-12262.
    >> Share

  285. WEISS MD, Freimer M, Leite MI, Maniaol A, et al
    Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
    J Neurol. 2024 Feb 24. doi: 10.1007/s00415-024-12209.
    >> Share

  286. OHNARI K, Hashimoto T, Iwanaka Y, Ohnari K, et al
    Dramatic improvement in refractory myasthenia gravis with eculizumab treatment: a case report.
    J Neurol. 2024 Feb 23. doi: 10.1007/s00415-024-12245.
    >> Share

  287. GREGULETZ P, Plotz M, Baade-Buttner C, Bien CG, et al
    Different pain phenotypes are associated with anti-Caspr2 autoantibodies.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12224.
    >> Share

  288. CUTILLO G, Rubin M, d'Amore G, Malcangi M, et al
    Infratentorial posterior reversible encephalopathy syndrome in INFbeta1a-treated multiple sclerosis patient.
    J Neurol. 2024 Feb 22. doi: 10.1007/s00415-024-12226.
    >> Share

  289. BIANCHI A, Matranga D, Patti F, Maniscalco L, et al
    The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
    J Neurol. 2024 Feb 16. doi: 10.1007/s00415-024-12214.
    >> Share

  290. HARDING KE, Kreft KL, Ben-Shlomo Y, Robertson NP, et al
    Prodromal multiple sclerosis: considerations and future utility.
    J Neurol. 2024 Feb 11. doi: 10.1007/s00415-023-12173.
    >> Share

  291. VANCURA J, Boyd NK, Vogel BN, Nagesh D, et al
    Rapidly progressive moyamoya vasculopathy stabilized with immunotherapy in aicardi-goutieres syndrome.
    J Neurol. 2024;271:1019-1022.
    >> Share

    January 2024
  292. BAJRAMI A, Tamanti A, Peloso A, Ziccardi S, et al
    Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-023-12179.
    >> Share

  293. BOUMAN PM, van Dam MA, Jonkman LE, Steenwijk MD, et al
    Isolated cognitive impairment in people with multiple sclerosis: frequency, MRI patterns and its development over time.
    J Neurol. 2024 Jan 30. doi: 10.1007/s00415-024-12185.
    >> Share

  294. NAUTA IM, Kessels RPC, Bertens D, Stam CJ, et al
    Neurophysiological brain function predicts response to cognitive rehabilitation and mindfulness in multiple sclerosis: a randomized trial.
    J Neurol. 2024 Jan 26. doi: 10.1007/s00415-024-12183.
    >> Share

  295. CENSI S, Bisaccia G, Gallina S, Tomassini V, et al
    Guillain-Barre syndrome and COVID-19 vaccination: a systematic review and meta-analysis.
    J Neurol. 2024 Jan 17. doi: 10.1007/s00415-024-12186.
    >> Share

  296. FENG G, Posa S, Sureshkumar A, Simpson S, et al
    Experiences of people with multiple sclerosis and clinicians in using cognitive behavioural therapies for hidden symptoms: a systematic review and meta-aggregation.
    J Neurol. 2024 Jan 14. doi: 10.1007/s00415-023-12116.
    >> Share

  297. ZHENG P, Sandroff BM, Motl RW
    Free-living ambulatory physical activity and cognitive function in multiple sclerosis: the significance of step rate vs. step volume.
    J Neurol. 2024 Jan 12. doi: 10.1007/s00415-023-12169.
    >> Share

  298. MAILLART E, Todesco E, Assoumou L, Beigneux Y, et al
    Humoral response after accelerated schedule of HBV vaccination in MS patients before anti-CD20 therapy.
    J Neurol. 2024 Jan 11. doi: 10.1007/s00415-023-12175.
    >> Share

  299. TRYFONOS C, Chrysafi M, Vadikolias K, Berberoglou L, et al
    Nutritional interventional studies in patients with multiple sclerosis: a scoping review of the current clinical evidence.
    J Neurol. 2024 Jan 4. doi: 10.1007/s00415-023-12140.
    >> Share

  300. LOREFICE L, Ferraro OE, Fenu G, Amato MP, et al
    Late-onset multiple sclerosis: disability trajectories in relapsing-remitting patients of the Italian MS Registry.
    J Neurol. 2024 Jan 3. doi: 10.1007/s00415-023-12152.
    >> Share

  301. FAVRUZZO F, Palmieri A, Giopato F, Cardellini D, et al
    Subacute transverse myelitis of possible vasculitic origin after SARS-CoV2 and Varicella-Zoster virus infections: a case report.
    J Neurol. 2024;271:75-78.
    >> Share

  302. NEUMANN B, Angstwurm K, Dohmen C, Mergenthaler P, et al
    Weaning and extubation failure in myasthenic crisis: a multicenter analysis.
    J Neurol. 2024;271:564-574.
    >> Share

  303. WIESENFARTH M, Stamminger T, Zizer E, Tumani H, et al
    Neurological manifestation of HEV infection: still a rare disease entity?
    J Neurol. 2024;271:386-394.
    >> Share

  304. MOSER T, Zimmermann G, Baumgartner A, Berger T, et al
    Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
    J Neurol. 2024;271:374-385.
    >> Share

  305. KUMPFEL T, Giglhuber K, Aktas O, Ayzenberg I, et al
    Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    J Neurol. 2024;271:141-176.
    >> Share

    December 2023
  306. AZZIMONTI M, Margoni M, Zanetta C, Genovese F, et al
    Tumefactive demyelinating lesions: a challenging first manifestation of multiple sclerosis.
    J Neurol. 2023 Dec 28. doi: 10.1007/s00415-023-12164.
    >> Share

  307. LIU M, Ren H, Wang L, Fan S, et al
    Prognostic and relapsing factors of primary autoimmune cerebellar ataxia: a prospective cohort study.
    J Neurol. 2023 Dec 23. doi: 10.1007/s00415-023-12128.
    >> Share

  308. IAFFALDANO P, Lucisano G, Guerra T, Patti F, et al
    Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12137.
    >> Share

  309. ANDORRA M, Freire A, Zubizarreta I, de Rosbo NK, et al
    Predicting disease severity in multiple sclerosis using multimodal data and machine learning.
    J Neurol. 2023 Dec 22. doi: 10.1007/s00415-023-12132.
    >> Share

  310. MISTRI D, Valsasina P, Storelli L, Filippi M, et al
    Monoaminergic network dysfunction and development of depression in multiple sclerosis: a longitudinal investigation.
    J Neurol. 2023 Dec 19. doi: 10.1007/s00415-023-12138.
    >> Share

  311. HABBESTAD A, Willumsen JS, Aarseth JH, Grytten N, et al
    Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study.
    J Neurol. 2023 Dec 14. doi: 10.1007/s00415-023-12047.
    >> Share

  312. COVEY TJ, Golan D, Sergott R, Wilken J, et al
    Peering further into the mind's eye: combining visual evoked potential and optical coherence tomography measures enhances insight into the variance in cognitive functioning in multiple sclerosis.
    J Neurol. 2023 Dec 13. doi: 10.1007/s00415-023-12075.
    >> Share

  313. ARROYO PEREIRO P, Munoz-Vendrell A, Leon Moreno I, Bau L, et al
    Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    J Neurol. 2023 Dec 12. doi: 10.1007/s00415-023-12135.
    >> Share

  314. TSAI CC, Jette S, Tremlett H
    Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.
    J Neurol. 2023 Dec 11. doi: 10.1007/s00415-023-12107.
    >> Share

  315. ABDELGAIED MY, Rashad MH, El-Tayebi HM, Solayman MH, et al
    The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial.
    J Neurol. 2023 Dec 9. doi: 10.1007/s00415-023-12113.
    >> Share

    November 2023
  316. MEYER-ARNDT L, Brasanac J, Gamradt S, Bellmann-Strobl J, et al
    Body mass, neuro-hormonal stress processing, and disease activity in lean to obese people with multiple sclerosis.
    J Neurol. 2023 Nov 27. doi: 10.1007/s00415-023-12100.
    >> Share

  317. MISTRI D, Tedone N, Biondi D, Vizzino C, et al
    Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment.
    J Neurol. 2023 Nov 26. doi: 10.1007/s00415-023-12102.
    >> Share

  318. JAKIMOVSKI D, Kavak KS, Coyle PK, Goodman AD, et al
    Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
    J Neurol. 2023 Nov 23. doi: 10.1007/s00415-023-12099.
    >> Share

  319. BISECCO A, Matrone F, Capobianco M, De Luca G, et al
    COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    J Neurol. 2023 Nov 20. doi: 10.1007/s00415-023-12084.
    >> Share

  320. SUN Y, Li G, Liu X, Zhao X, et al
    Cerebral glucose hypometabolism and hypoperfusion of cingulate gyrus: an imaging biomarker of autoimmune encephalitis with psychiatric symptoms.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12051.
    >> Share

  321. KENNEDY PGE, George W, Yu X
    The elusive nature of the oligoclonal bands in multiple sclerosis.
    J Neurol. 2023 Nov 9. doi: 10.1007/s00415-023-12081.
    >> Share

  322. DI FILIPPO M, Ferraro D, Ragonese P, Prosperini L, et al
    SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose.
    J Neurol. 2023 Nov 3. doi: 10.1007/s00415-023-12034.
    >> Share

  323. FROHLICH K, Mrochen A, Wang R, Haupenthal D, et al
    Cerebral lesions sites in neurosarcoidosis: a lesion mapping study.
    J Neurol. 2023;270:5392-5397.
    >> Share

  324. JEANTIN L, Shor N, Pallix-Guyot M, Roos-Weil D, et al
    Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod.
    J Neurol. 2023 Nov 1. doi: 10.1007/s00415-023-12055.
    >> Share

    October 2023
  325. MANTERO V, Cordano C, Balgera R, Basilico P, et al
    Serum sickness in a multiple sclerosis patient treated with ocrelizumab.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12082.
    >> Share

  326. KAPPOS L, Traboulsee A, Li DKB, Bar-Or A, et al
    Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-11943.
    >> Share

  327. DELGADO SR, Faissner S, Linker RA, Rammohan K, et al
    Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.
    J Neurol. 2023 Oct 31. doi: 10.1007/s00415-023-12007.
    >> Share

  328. RIVEL M, Achiron A, Stern Y, Zeilig G, et al
    Emotional burden among MS patients: associations between specific chronic pain diagnoses and psychological features.
    J Neurol. 2023 Oct 24. doi: 10.1007/s00415-023-12048.
    >> Share

  329. ONTANEDA D, Chitnis T, Rammohan K, Obeidat AZ, et al
    Identification and management of subclinical disease activity in early multiple sclerosis: a review.
    J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021.
    >> Share

  330. ZINGANELL A, Gobel G, Berek K, Hofer B, et al
    Multiple sclerosis in the elderly: a retrospective cohort study.
    J Neurol. 2023 Oct 19. doi: 10.1007/s00415-023-12041.
    >> Share

  331. SELMAJ K, Cree BAC, Barnett M, Thompson A, et al
    Multiple sclerosis: time for early treatment with high-efficacy drugs.
    J Neurol. 2023 Oct 18. doi: 10.1007/s00415-023-11969.
    >> Share

  332. RAVANO V, Piredda GF, Krasensky J, Andelova M, et al
    Tract-wise microstructural analysis informs on current and future disability in early multiple sclerosis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-12023.
    >> Share

  333. MANZANO GS, McEntire C, Venna N
    Case report of palatal tremor as a feature of CASPR2 autoimmune encephalitis.
    J Neurol. 2023 Oct 11. doi: 10.1007/s00415-023-11992.
    >> Share

  334. ZHANG Z, Wang Z, Du X, Huang X, et al
    Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
    J Neurol. 2023 Oct 7. doi: 10.1007/s00415-023-12036.
    >> Share

  335. KRAKER JA, Chen JJ
    An update on optic neuritis.
    J Neurol. 2023;270:5113-5126.
    >> Share

  336. BRISCA G, Marini C, Buratti S, Mariani M, et al
    Acute pediatric encephalitis: etiology, course, and outcome of a 12-year single-center immunocompetent cohort.
    J Neurol. 2023;270:5034-5047.
    >> Share

  337. WANG R, Sun D, Du Q, Shi Z, et al
    Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
    J Neurol. 2023;270:5085-5089.
    >> Share

    September 2023
  338. RODRIGUEZ DE VERA GOMEZ P, Mendez Muros M, Torres Cuadro A, Toyos Saenz de Miera FJ, et al
    Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis.
    J Neurol. 2023 Sep 29. doi: 10.1007/s00415-023-11995.
    >> Share

  339. LI Y, Saul A, Taylor B, Ponsonby AL, et al
    Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
    J Neurol. 2023 Sep 28. doi: 10.1007/s00415-023-11980.
    >> Share

  340. KERNER C, Kotobelli K, Appleby BS, Cohen ML, et al
    Pathological findings in autoimmune encephalitis autopsy specimens from cases of suspected prion disease.
    J Neurol. 2023 Sep 27. doi: 10.1007/s00415-023-12003.
    >> Share

  341. WEEDA MM, van Nederpelt DR, Twisk JWR, Brouwer I, et al
    Multimodal MRI study on the relation between WM integrity and connected GM atrophy and its effect on disability in early multiple sclerosis.
    J Neurol. 2023 Sep 17. doi: 10.1007/s00415-023-11937.
    >> Share

  342. FILIPPI M, Grimaldi L, Conte A, Totaro R, et al
    Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    J Neurol. 2023 Sep 16. doi: 10.1007/s00415-023-11955.
    >> Share

  343. GRIFFITH SP, Wesselingh R, Seery N, Rushen T, et al
    Characterizing cognitive function in patients with autoimmune encephalitis: an Australian prospective study.
    J Neurol. 2023 Sep 14. doi: 10.1007/s00415-023-11967.
    >> Share

  344. MCARTHUR C, Daruwalla C, Jayeskara M, Brown JWL, et al
    Robust real-world evidence: optimising disease-modifying treatments for multiple sclerosis.
    J Neurol. 2023 Sep 12. doi: 10.1007/s00415-023-11984.
    >> Share

  345. DI STEFANO V, Alonge P, Rini N, Militello M, et al
    Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome.
    J Neurol. 2023 Sep 8. doi: 10.1007/s00415-023-11970.
    >> Share

  346. JACOBS BM, Tank P, Bestwick JP, Noyce AJ, et al
    Modifiable risk factors for multiple sclerosis have consistent directions of effect across diverse ethnic backgrounds: a nested case-control study in an English population-based cohort.
    J Neurol. 2023 Sep 7. doi: 10.1007/s00415-023-11971.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016